Search

Your search keyword '"The Genotype to Phenotype Japan (G2P-Japan)"' showing total 3 results
Start Over Author "The Genotype to Phenotype Japan (G2P-Japan)" Publisher oxford university press (oup)
3 results on '"The Genotype to Phenotype Japan (G2P-Japan)"'

1. SARS-CoV-2 B.1.617 mutations L452 and E484Q are not synergistic for antibody evasion

Author

Ferreira, Isabella, Kemp, Steven, Datir, Rawlings, Saito, Akatsuki, Meng, Bo, Rakshit, Partha, Takaori-Kondo, Akifumi, Kosugi, Yusuke, Uriu, Keiya, Kimura, Izumi, Shirakawa, Kotaro, Abdullahi, Adam, The CITIID-NIHR BioResource COVID-19 Collaboration, The Indian SARS-CoV-2 Genomics Consortium (INSACOG), Agarwal, Anurag, Ozono, Seiya, Tokunaga, Kenzo, Genotype to Phenotype Japan (G2P-Japan) Consortium, Sato, Kei, and Gupta, Ravindra K.

Subjects
infectivity, SARS-CoV-2, COVID-19, Indian variant, covid-19 vaccines, vaccines, evasion, fitness, resistance, spike mutation, antibodies, pathogenicity, antibody escape, neutralizing antibodies, mutation, B.1.617
Abstract

The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that two key mutations seen in the receptor binding domain L452R and E484Q would have additive effects on evasion of neutralising antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine elicited neutralising antibodies by L452R and E484Q but lack of synergistic loss of sensitivity., SARS-CoV-2 B.1.617系統（俗称「インド株」）のL452R変異とE484Q変異は 中和抗体感受性の低下において、相加的な抵抗性を示さない. 京都大学プレスリリース. 2021-08-24.

Published
2021

2. SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion

Author

Ferreira, Isabella ATM, Kemp, Steven A, Datir, Rawlings, Saito, Akatsuki, Meng, Bo, Rakshit, Partha, Takaori-Kondo, Akifumi, Kosugi, Yusuke, Uriu, Keiya, Kimura, Izumi, Shirakawa, Kotaro, Abdullahi, Adam, Agarwal, Anurag, Ozono, Seiya, Tokunaga, Kenzo, Sato, Kei, Gupta, Ravindra K, CITIID-NIHR BioResource COVID-19 Collaboration, Indian SARS-CoV-2 Genomics Consortium, Genotype To Phenotype Japan (G2P-Japan) Consortium, Sato, Kei [0000-0003-4431-1380], Gupta, Ravindra K [0000-0001-9751-1808], and Apollo - University of Cambridge Repository

Subjects
COVID-19 Vaccines, India, evasion, Antibodies, Viral, resistance, spike mutation, Chlorocebus aethiops, Animals, Humans, neutralizing antibodies, Vero Cells, BNT162 Vaccine, Immune Evasion, SARS-CoV-2, infectivity, Serine Endopeptidases, COVID-19, Indian variant, Antibodies, Neutralizing, fitness, HEK293 Cells, Mutation, Spike Glycoprotein, Coronavirus, antibody escape, Angiotensin-Converting Enzyme 2, B.1.617, Protein Binding
Abstract

The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine-elicited neutralizing antibodies by L452R and E484Q but lack of synergistic loss of sensitivity.

Published
2021

3. SARS-CoV-2 B.1.617 mutations L452 and E484Q are not synergistic for antibody evasion

Author

80728270, Ferreira, Isabella, Kemp, Steven, Datir, Rawlings, Saito, Akatsuki, Meng, Bo, Rakshit, Partha, Takaori-Kondo, Akifumi, Kosugi, Yusuke, Uriu, Keiya, Kimura, Izumi, Shirakawa, Kotaro, Abdullahi, Adam, The CITIID-NIHR BioResource COVID-19 Collaboration, The Indian SARS-CoV-2 Genomics Consortium (INSACOG), Agarwal, Anurag, Ozono, Seiya, Tokunaga, Kenzo, Genotype to Phenotype Japan (G2P-Japan) Consortium, Sato, Kei, Gupta, Ravindra K., 80728270, Ferreira, Isabella, Kemp, Steven, Datir, Rawlings, Saito, Akatsuki, Meng, Bo, Rakshit, Partha, Takaori-Kondo, Akifumi, Kosugi, Yusuke, Uriu, Keiya, Kimura, Izumi, Shirakawa, Kotaro, Abdullahi, Adam, The CITIID-NIHR BioResource COVID-19 Collaboration, The Indian SARS-CoV-2 Genomics Consortium (INSACOG), Agarwal, Anurag, Ozono, Seiya, Tokunaga, Kenzo, Genotype to Phenotype Japan (G2P-Japan) Consortium, Sato, Kei, and Gupta, Ravindra K.

Abstract

The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that two key mutations seen in the receptor binding domain L452R and E484Q would have additive effects on evasion of neutralising antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine elicited neutralising antibodies by L452R and E484Q but lack of synergistic loss of sensitivity.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results